Cantitate/Preț
Produs

Pharmaceutical Patents in Europe: Stockholm Studies in Law, cartea 3

Autor Bengt Domeij
en Limba Engleză Hardback – 29 feb 2000
The pharmaceutical industry and patent legislation are inextricably linked. Pharmaceutical companies could not exist without some guarantee that they can recoup the cost of developing a new product. European patent law offers this opportunity, as it allows companies to exclude competition for a specific product for a fixed time scale. In Pharmaceutical Patents in Europe the current legal patent situation is examined by a detailed analysis of case law from the European Patent Office (EPO), the international body created with the signing of the European Patent Convention (EPC). Aspects of European patent law not primarily regulated in the EPC, for example Supplementary Protection Certificates and infringement matters, are examined in the setting provided by EC law and domestic laws of European states. This book is written for the reader who understands the main characteristics of patent law and is looking for a practitioner's text on the European pharmaceutical patent law scene. Moreover, the author's remarks can help all readers to look at the field with fresh eyes.
Citește tot Restrânge

Din seria Stockholm Studies in Law

Preț: 89671 lei

Preț vechi: 109355 lei
-18% Nou

Puncte Express: 1345

Preț estimativ în valută:
17164 17997$ 14182£

Carte indisponibilă temporar

Doresc să fiu notificat când acest titlu va fi disponibil:

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9789041113481
ISBN-10: 9041113487
Pagini: 350
Dimensiuni: 167 x 249 x 28 mm
Greutate: 0.73 kg
Editura: Brill
Colecția Brill | Nijhoff
Seria Stockholm Studies in Law


Cuprins

Acknowledgements. Foreword. Abbreviations. 1. Industrial Applicability. 2. Sufficiency of Disclosure. 3. The Claims. 4. Novelty. 5. New Medical Uses of Known Compounds. 6. Inventive step. 7. Supplementary Patent Protection. 8. Patent Infringement. 9. References. 10. Index.

Recenzii

'It should certainly be on the bookshelf of any pharmaceutical practitioner.'
Bio-Sciences Law Review, 4:1.